Adversity and Its Association With the Development and Expression of Rheumatic Diseases (RD)

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Status: Not yet enrolling

Conditions: RhA - Rheumatoid Arthritis

Treatments: Other: Cellular senescence; Genetic: Expression of CDKN2A /p16INK4a; Genetic: Telomere length; Other: Health Assessment Questionnaire (HAQ); Other: Depression, Anxiety and Stress Scale (DASS-21); Other: Rheumatic diseases Mistreatment Scale (RDMS); Other: WHOQOL-BREF; Other: Brief Resilient Coping Scale; Other: Immunophenotype of leukocyte subpopulations; Other: Routine assessment of patient index data 3 (RAPID-3)

Study type: Observational

Funder types: Other

Identifiers

NCT06386380

IRE-4906

Details and patient eligibility

About

Epidemiological evidence shows that adverse experiences, particularly, but not exclusively in childhood, are predictors of poor long-term health outcomes and certain social domains. In the field of rheumatic diseases, traumatic events, not only in childhood, have been associated with hospitalization, chronic pain, inflammation, worse outcomes, severity of the disease, and mortality. Some mechanisms proposed to explain the association between the experience of adversity and the development of chronic diseases include an impact on the physiology of immune system cells, gene expression due to DNA modification, and cellular senescence.

With this background, the investigators wonder if, for patients with rheumatoid arthritis, the presence of adversity understood as a history of violence in childhood and abuse due to suffering from rheumatoid arthritis is associated with markers of cellular senescence and with the severity of illness.

Full description

To answer this question, the investigators proposed conducting a study on outpatients diagnosed with rheumatoid arthritis treated at the INCMNSZ.

Patients who agree to participate will be asked to answer some questionnaires to report their perception of child abuse and abuse derived from suffering from rheumatoid arthritis, disease activity, disability, quality of life, anxiety, stress, depression, and resilience.

Additionally, a peripheral blood sample will be taken to evaluate cellular senescence through CD27, CD28, and CD57 expression, the relative expression of the p16INK4a gene in CD3+ lymphocytes, HLA-DR, CD25, and CD69, and telomere length. Finally, the expression of the severity of the disease will be determined.

Enrollment: 110 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a rheumatoid arthritis diagnosis, according to their primary rheumatologist who agrees to participate

Exclusion criteria

• Patients with a not confirmed rheumatoid arthritis diagnosis

Trial design

110 participants in 1 patient group

Patients with rheumatoid arthritis

Description:

Patients with rheumatoid arthritis outpatients from the National Institute of Medical Sciences

Treatment:

Other: Health Assessment Questionnaire (HAQ)

Other: Depression, Anxiety and Stress Scale (DASS-21)

Other: Brief Resilient Coping Scale

Other: Cellular senescence

Other: Immunophenotype of leukocyte subpopulations

Genetic: Telomere length

Other: Rheumatic diseases Mistreatment Scale (RDMS)

Other: WHOQOL-BREF

Genetic: Expression of CDKN2A /p16INK4a

Other: Routine assessment of patient index data 3 (RAPID-3)